Navigation Links
Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Date:2/11/2008

ll receive the PROMUS Stent and half will receive either the Cypher or the Endeavor Stent to attain a 2:1:1 ratio of PROMUS, Cypher, and Endeavor Stents respectively. The primary endpoint of the registry will be the rate of major cardiac events (cardiac death, all myocardial infarction and target vessel revascularization) at 12 months.

The PROMUS, Cypher and Endeavor Stents have previously been investigated in randomized clinical trials. Twelve-month data from the SPIRIT III Trial, presented in October 2007 at the Transcatheter Cardiovascular Therapeutics conference in Washington, confirmed earlier positive clinical results for the XIENCE V (PROMUS) Stent. This trial compared XIENCE V (PROMUS) with the market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Stent, demonstrating non-inferiority in the primary endpoint of in-segment late loss at eight months with no safety concerns at 12 months.

Boston Scientific is the first company to offer European physicians and their patients a choice of two distinct drug-eluting stent platforms: TAXUS and PROMUS.

TAXUS and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of the Abbott Laboratories group of companies. Endeavor is a trademark of Medtronic Vascular Incorporated. Cypher is a trademark of Cordis Corporation, a Johnson & Johnson company.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estim
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007
2. Boston Scientific to Participate in Merrill Lynch Conference
3. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
4. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
5. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
6. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
7. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
8. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
9. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
10. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
(Date:11/24/2014)... One of the most extensive, widely cited digital ... now available to high school and junior college students and ... international society for optics and photonics , announced today that ... Library available to high schools for free and two-year ... to all areas of life in today’s world,” said SPIE ...
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated ... company committed to the fostering and monetization of ... v. VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  ... No. 3:13-cv-03496-M, both in the United States District ... Texas . On November ...
(Date:11/22/2014)... VA (PRWEB) November 21, 2014 During ... who understood the need to surround himself with great ... CEO and entrepreneur, his friends often marveled at his ... he lived his life and -- even with his ... for the Alzheimer’s disease that would ultimately take his ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... , , , ... ADL), a US-based pharmaceutical company with major assets in China, announced today ... of the Company as " Radient Pharmaceuticals Corporation" . ... will be "RPC" . The Company has filed an ...
... , SEATTLE, Sept. 18 Omeros Corporation ... 6.82 million shares of its common stock. Omeros is ... products focused on inflammation and disorders of the central nervous ... for the initial public offering is $10.00 to $12.00 per ...
... , , SAN MATEO, ... a biopharmaceutical company focused on developing and commercializing novel pain management ... is scheduled to present at the UBS Global Life Sciences Conference, ... City. , , Mr. DiTonno and Stephen ...
Cached Biology Technology:AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 2AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 3AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 4AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 5Omeros Commences Initial Public Offering of Common Stock 2Omeros Commences Initial Public Offering of Common Stock 3NeurogesX to Present at UBS Global Life Sciences Conference 2NeurogesX to Present at UBS Global Life Sciences Conference 3
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... recorded during a record-setting expedition have yielded new insights ... in the cold, dark, and highly pressurized habitats of ... Natalya Gallo of Scripps Institution of Oceanography at ... DEEPSEA CHALLENGE expedition, a project led by James Cameron ...
... his doctoral student Nicole Bance are among an international group ... compounds capable of killing the influenza virus. , Working ... can be a killer, the scientists have advanced previous researchers, ... influenza replicates and spreads. , Their new compounds will ...
... 21, 2013) Cardiovascular disease specialists at Florida Hospital Pepin ... with the University of South Florida announced they have enrolled ... gene therapy for the treatment of heart failure after ischemic ... tissue by encouraging the body to deploy more stem cells ...
Cached Biology News:Vibrant mix of marine life found at extreme ocean depths, Scripps analysis reveals 2Vibrant mix of marine life found at extreme ocean depths, Scripps analysis reveals 3Influenza study: Meet virus' new enemy 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 3
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,669-3) ... assistance. ID clarifier: barcoded Mfr ...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
Biology Products: